Skin autofluorescence as a measure of advanced glycation endproduct deposition: A novel risk marker in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 19, Issue 6, 2010, Pages 527-533

  Smit, Andries J ^a   Gerrits, Esther G ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ISALA HOSPITAL   (Netherlands)

Author keywords

advanced glycation endproducts; diabetes; skin autofluorescence

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR;

AUTOFLUORESCENCE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; DISEASE MARKER; HUMAN; KIDNEY FAILURE; KIDNEY GRAFT; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SKIN AUTOFLUORESCENCE;

BIOLOGICAL MARKERS; CHRONIC DISEASE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY DISEASES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SKIN; SPECTROMETRY, FLUORESCENCE; TIME FACTORS;

EID: 78049268119     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32833e9259     Document Type: Review

References (50)

1. Holman RR, Paul SK, Bethel MA, et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359:1577-1589.
2. Hartog JWL, Gross S, Oterdoom LH, et al. Skin autofluorescence is an independent predictor of graft loss in renal transplant recipients. Transplantation 2009; 87:1069-1077.
3. Kern EFO, Erhard P, Sun W, et al. Early urinary markers of diabetic kidney disease: a nested case-control study from the Diabetes Control and Com plications Trial (DCCT). Am J Kidney Dis 2010; 55:824-834.
4. Genuth S, Sun W, Cleary P, et al. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes 2005; 54:3103-3111.
5. D'Agati V, Schmidt AM. RAGE and the pathogenesis of chronic kidney disease. Nat Rev Nephrol 2010; 6:352-360.
6. Koyama H, NishizawaY. AGEs/RAGEs in CKD: irreversible metabolic memory road toward CVD? Eur J Clin Invest 2010. [Epub ahead of print]
7. Kumagai T, Nangaku M, Kojima I, et al. Glyoxalase I overexpression ameliorates renal ischemia-reperfusion injury in rats. Am J Physiol Renal Physiol 2009; 296:F912-F921.
8. Uribarri J, Cai W, Sandu O, et al. Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann N Y Acad Sci 2005; 1043:461-466.
9. Thornalley PJ, Rabbani N. Highlights and hotspots of protein glycation in end-stage renal disease. Semin Dial 2009; 22:400-404.
10. Yan SF, Ramasamy R, Schmidt AM. The RAGE axis: a fundamental mechan-ism signaling danger to the vulnerable vasculature. Circ Res 2010; 106:842-853.
11. Linden E, Cai W, He JC, et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol 2008; 3:691-698.
12. Meerwaldt R, Graaff R, Oomen PH, et al. Simple noninvasive assessment of advanced glycation endproduct accumulation. Diabetologia 2004; 47:1324-1330.
13. Meerwaldt R, Hartog JW, Graaff R, et al. Skin autofluorescence, a measure of cumulative metabolic stress and advanced glycation end products, predicts mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16:3687-3693.
14. Meerwaldt R, Lutgers HL, Links TP, et al. Skin autofluorescence is a strong predictor of cardiac mortality in diabetes. Diabetes Care 2007; 30:107-112.
15. Lutgers HL, Graaff R, Links TP, et al. Skin autofluorescence as a noninvasive marker of vascular damage in patients with type 2 diabetes mellitus. Diabetes Care 2006; 29:2654-2659.
16. Mulder DJ. Skin autofluorescence, a novel marker for glycemic and oxidative stress derived advanced glycation endproducts. In: Skin autofluorescence in cardiovascular disease: a noninvasive approach for assessing inflammatory and oxidative stress. Wageningen, the Netherlands: Ponsen & Looijen; 2007. Chapter 2. p. 57.
17. Meerwaldt R. Simple non-invasive assessment of advanced glycation endproduct accumulation. In: Skin autofluorescence and advanced glycation endproducts. Wageningen, the Netherlands: Ponsen & Looijen; 2005. Chapter 6. p. 71.
18. Maynard JD, Rohrscheib M, Way JF, et al. Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. Diabetologia 2007; 30:1120-1124.
19. Xu LY, Liu Y, Zhang G, et al. Technology of advanced glycation endproducts fluorescence measurement and precorrection (in Chinese). Guang Pu Xue Yu Guang Pu Fen Xi 2010; 30:230-232.
20. Sell DR, Nemet I, Monnier VM. Partial characterization of the molecular nature of collagen-linked fluorescence: role of diabetes and end-stage renal disease. Arch Biochem Biophys 2010; 493:192-206.
21. Januszewski AS, Sachithanandan N, Karschimkus C, et al. In: Ninth international symposium on the Maillard reaction; Munich, Germany; 2007. Abstract SVI-05.
22. Pozzi A, Zent R, Chetyrkin S, Borza C, et al. Modification of collagen IV by glucose or methylglyoxal alters distinct mesangial cell functions. J Am Soc Nephrol 2009; 20:2119-2125.
23. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulo sclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003; 162:1123-1137.
24. Tan ALY, Sourris KC, Harcourt BE, et al. Disparate effects on renal and oxidative parameters following RAGE deletion, AGE accumulation inhibition, or dietary AGE control in experimental diabetic nephropathy. Am J Physiol Renal Physiol 2010; 298:F763-F770.
25. Semba RD, Fink JC, Sun K, Bandinelli S, et al. Carboxymethyl-lysine, an advanced glycation end product, and decline of renal function in older community-dwelling adults. Eur J Nutr 2009; 48:38-44.
26. Hou FF, Ren H, Owen WF Jr, et al. Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol 2004; 15:1889-1896.
27. Gerrits EG, Lutgers HL, Kleefstra N, et al. Skin autofluorescence: a tool to identify type 2 diabetic patients at risk for developing microvascular complications. Diabetes Care 2008; 31:517-521.
28. Lutgers HL, Gerrits EG, Graaff R, et al. Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. Diabetologia 2009; 52:789-797.
29. Chabroux S, Canoü?-Poitrine F, Reffet S, et al. Advanced glycation end products assessed by skin autofluorescence in type 1 diabetics are associated with nephropathy, but not retinopathy. Diabetes Metab 2010; 36:152-157.
30. Conway B, Edmundowicz D, Matter N, et al. Skin fluorescence correlates strongly with coronary artery calcification severity in type 1 diabetes. Diabetes Technol Therap 2010; 12:339-345.
31. Ueno H, Koyama H, Tanaka S, et al. Skin autofluorescence, a marker for advanced glycation end product accumulation, is associated with arterial stiffness in patients with end-stage renal disease. Metabolism 2008; 57:1452-1457.
32. Gerrits EG, Smit AJ, Bilo HJG. AGEs, autofluorescence and renal function. Nephrol Dial Transplant 2009; 24:710-713.
33. McIntyre NJ, Chesterton LJ, et al. Tissue-advanced glycation end product concentration in dialysis patients. Clin J Am Soc Nephrol 2010; 5:51-55.
34. Hartog JW, Hummel YM, VoorsAA, et al. Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients. J Card Fail 2008; 14:596-602.
35. Ueno H, Koyama H, Fukumoto S, et al. AGE, carotid atherosclerosis, and circulating endothelial progenitor cells in patients with end-stage renal dis ease. Metabolism 2010. [Epub ahead of print]
36. Floridi A, Antolini F, Galli F, et al. Daily haemodialysis improves indices of protein glycation. Nephrol Dial Transplant 2002; 17:871-878.
37. Baragetti I, Furiani S, Vettoretti S, et al. Role of vitamin E-coated membrane in reducing advanced glycation end products in hemodialysis patients: a pilot study. Blood Purificat 2006; 24:369-376.
38. Lee HY, Choi HY, Park HC, et al. Changing prescribing practice in CAPD patients in Korea: increased utilization of low GDP solutions improves patient outcome. Nephrol Dial Transplant 2006; 21:2893-2899.
39. Hartog JW, Smit AJ, van Son WJ, et al. Advanced glycation endproducts in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction. Am J Kidney Dis 2004; 43:966-975.
40. Hartog JW, de Vries AP, Bakker SJ, et al. Risk factors for chronic transplant dysfunction and cardiovascular disease are related to accumulation of advanced glycation end-products in renal transplant recipients. Nephrol Dial Transplant 2006; 21:2263-2269.
41. Soulis-Liparota T, Cooper M, Papazoglou D, et al. Retardation by aminogua-nidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozocin-induced diabetic rat. Diabetes 1991; 40:1328-1334.
42. Joshi D, Gupta R, Dubey A, et al. TRC4186, a novel AGE-breaker, improves diabetic cardiomyopathy and nephropathy in Ob-ZSF1 model of type 2 diabetes. J Cardiovasc Pharmacol 2009; 54:72-81.
43. Williams ME, Bolton WK, Khalifah RG, et al. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. Am J Nephrol 2007; 27:605-614.
44. Karachalias N, Babaei-Jadidi R, Rabbani N, Thornalley PJ. Increased protein damage in renal glomeruli, retina, nerve, plasma and urine and its prevention by thiamine and benfotiamine therapy in a rat model of diabetes. Diabetologia 2010; 53:1506-1516.
45. Rabbani N, Alam S, Riaz S, et al. High dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a pilot randomised, double-blind, placebo-controlled study. Diabetologia 2008; 52:208-212.
46. Alkhalaf A, Klooster A, van Oeveren W, et al. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Diabetes Care 2010. [Epub ahead of print]
47. Forbes JM, Thorpe SR, Thallas-Bonke V, et al. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J Am Soc Nephrol 2005; 16:2363-2372.
48. Thomas MC, Tikellis C, Burns WM, et al. Interactions between renin angio-tensin system and advanced glycation in the kidney. J Am Soc Nephrol 2005; 16:2976-2984.
49. Busch M, Franke S, Wolf G, et al. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension. Nephron Clin Pract 2008; 108:c291-c297.
50. Vlassara H, Uribarri J, Ferrucci L, Cai W, et al. Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons. Semin Nephrol 2009; 29:594-603.